The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Sarcoid-like granulomatosis (endo-/extrathoracic)
Publications
Checkpoint inhibitor-induced sarcoid choroidal granulomas.
American journal of ophthalmology case reports 2020 Jun;18;100652 — 2020 Jun — 100652
[Nivolumab and sarcoid reaction in lung cancer treatment].
Revue des maladies respiratoires 2019 Feb;36;230-232 — 2019 Feb — 230-232
Nivolumab-Induced Development of Pulmonary Sarcoidosis in Renal Cell Carcinoma.
Clinical nuclear medicine 2017 Sep;42;728-729 — 2017 Sep — 728-729
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Mar;35;709-717 — 2017 Mar — 709-717
Pulmonary sarcoid-like granulomatosis induced by nivolumab.
The British journal of dermatology 2017 Apr;176;1060-1063 — 2017 Apr — 1060-1063
Danlos FX, Pagès C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A, Lebbé C
Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.
Chest 2016 May;149;e133-6 — 2016 May — e133-6
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013;; — 2013
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
The New England journal of medicine 2012 Jun 28;366;2455-65 — 2012 Jun 28 — 2455-65